Monday, March 23, 2015 4:16:04 PM
[?IMG]
Hagens Berman Announces the Filing of a Class Action Lawsuit Against Arrowhead Research Corporation, Inc. (NASDAQ: ARWR)
SAN FRANCISCO—Nov. 4, 2014—Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors that a class action lawsuit has been filed against Arrowhead Research Corporation (NASDAQ: ARWR) (“Arrowhead” or “the Company”). The suit is pending in U.S. District Court for the Central District of California and investors have until December 9, 2014 to move for lead plaintiff.
The complaint has been filed on behalf of investors who purchased or otherwise acquired Arrowhead Research Corporation securities between August 12, 2014 and October 8, 2014, inclusive (the “Class Period”). If your purchases fall in the Class Period, you may contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000, emailing ARWR@hbsslaw.com or visiting http://hb-securities.com/investigations/ARWR.
Arrowhead is a biopharmaceutical company, whose research focuses on RNA Interference (“RNAi”) therapies, including an experimental hepatitis B therapy called ARC-520. Throughout the Class Period, Defendants repeatedly suggested that ARC-520 was performing better in testing and was more effective than it actually was. On August 12, 2014, Defendants held their Q3 earnings call, and commented on the progress of the ARC-520 Phase IIa study. On that call, Defendants hinted at the successes of the Phase IIa study, and indicated that the drug was achieving high viral reduction results in human testing.
Yet the truth was revealed on October 8, 2014 when Arrowhead announced the final results of the Phase IIa study which showed that the test results for ARC-520 fell well short of what Defendants suggested in August. On this news, Arrowhead’s stock price fell $5.48 per share, or almost 44%, to close at $7.03 per share on October 8, 2014.
“There is a fine line between optimism and deceit,” said Mr. Kathrein. “The way Defendants presented their Phase IIa study in August crossed that line, and investors were misled and suffered losses as a result.”
Recent BNTC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/06/2024 05:15:18 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 09:19:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/21/2023 12:05:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/21/2023 12:00:53 PM
- Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 09:26:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 09:13:45 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM